Compare Amphastar Pharmaceuticals Inc (AMPH) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Marathon Petroleum Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Marathon Petroleum Corp trades at $300.23 (market cap $82.83B). The key difference: Marathon Petroleum Corp is far larger — about 100.3× Amphastar Pharmaceuticals Inc's market cap, and Marathon Petroleum Corp pays a 1.38% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MPC | |
|---|---|---|
Market Cap | $826.08M | $82.83B |
Sector | Health | Energy |
52-Week High | $30.81 | $283.74 |
52-Week Low | $16.87 | $158.59 |
Enterprise Value | $1.22B | $115.01B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% on the day, with a bearish technical signal from moving averages. Recent earnings missed estimates in Q1 2026, with revenue of $171.2 million and adjusted EPS of $0.42 versus $0.70 expected. The company is shifting focus toward proprietary drugs and biosimilars for growth, as noted at recent investor conferences.
Outlook is mixed: valuation ratios appear reasonable with P/E of 11.29 and EV/EBITDA of 6.32, but earnings misses and a Zacks Strong Sell rating highlight near-term risks. The consensus price target of $20.40 suggests modest upside if execution improves, though legal scrutiny and competitive pressures remain concerns.
Marathon Petroleum (MPC) trades at $296.88, up 4.63% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages, though oscillators indicate overbought conditions. Fundamentally, MPC reported Q1 2026 EPS of $1.65, beating expectations, with a robust ROE of 27.92%. Recent news highlights refining capacity constraints supporting crack spreads, with geopolitical tensions influencing oil prices.
Outlook remains positive with 76% analyst buy ratings and a consensus price target of $278.38, though current price exceeds this. Key risks include volatile oil markets, regulatory scrutiny from AI pricing lawsuits, and declining operating cash flow. The stock offers value with a P/S of 0.63, but investors should monitor Q2 2026 earnings on August 4 for margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
